N. Voronkova

发表

Virus‐specific antibody titres in different phases of hepatitis C virus infection

A. Archakov, O. Isaeva, M. Michailov, 2002, Journal of viral hepatitis.

Interim results of a Phase Ib / IIa study of the entry inhibitor myrcludex B in chronic hepatitis D infected patients

W. Haefeli, T. Lehr, M. Haag, 2016 .

Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial.

W. Haefeli, M. Haag, U. Merle, 2022, The Lancet. Infectious diseases.

GS-13-Final results of a multicenter, open-label phase 2 clinical trial (MYR203) to assess safety and efficacy of myrcludex B in cwith PEG-interferon Alpha 2a in patients with chronic HBV/HDV co-infection

W. Haefeli, S. Ciesek, H. Wedemeyer, 2019, Journal of Hepatology.

CHRONIC HEPATITIS B VIRUS INFECTION IN PREGNANCY: STRATEGIES OF ANTIVIRAL THERAPY

P. Bogomolov, N. Voronkova, A. O. Bueverov, 2016 .

Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study.

Thorsten Lehr, Mathias Haag, Antje Blank, 2016, Journal of hepatology.

Overview of clinical guidelines on the management of hepatitis E

P. Bogomolov, N. Voronkova, E. Liusina, 2019, Sechenov Medical Journal.

Final results of a multicenter, open-label phase 2b clinical trial to assess safety and efficacy of Myrcludex B in combination with Tenofovir in patients with chronic HBV/HDV co-infection

W. Haefeli, M. Haag, M. Schwab, 2018 .